Identification of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using PandaOmics - An AI-Enabled Biological Target Discovery Platform.
1. Front Aging Neurosci. 2022 Jun 28;14:914017. doi: 10.3389/fnagi.2022.914017. eCollection 2022. Identification of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using PandaOmics - An AI-Enabled Biological Target Discovery Platform. Pun FW(1), Liu BHM(1), Long X(1), Leung HW(1), Leung GHD(1), Mewborne QT(2), Gao J(2), Shneyderman A(1), Ozerov IV(1), Wang J(1), Ren F(1), Aliper A(1), Bischof E(3)(4), Izumchenko E(5), Guan X(6), Zhang K(2)(7), Lu B(8), Rothstein JD(9)(10), Cudkowicz ME(11), Zhavoronkov A(1)(12). Author information: (1)Insilico Medicine Hong Kong Ltd., Hong Kong Science and Technology Park, Hong Kong, Hong Kong SAR, China. (2)Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL, United States. (3)College of Clinical Medicine, Shanghai University of Medicine and Health Sciences, Shanghai, China. (4)International Center for Multimorbidity and Complexity in Medicine (ICMC), Universität Zürich, Zurich, Switzerland. (5)Department of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago, IL, United States. (6)4B Technologies Limited, Suzhou BioBay, Suzhou, China. (7)Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, United States. (8)School of Pharmaceutical Sciences, IDG/McGovern Institute for Brain Research, Tsinghua University, Beijing, China. (9)Brain Science Institute, Johns Hopkins University School of Medicine, Baltimore, MD, United States. (10)Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, United States. (11)Healey & AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States. (12)Buck Institute for Research on Aging, Novato, CA, United States. Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disease with ill-defined pathogenesis, calling for urgent developments of new therapeutic regimens. Herein, we applied PandaOmics, an AI-driven target d